blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3740210

EP3740210 - THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYLATION IN CANCER [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  17.05.2024
Database last updated on 15.06.2024
FormerRequest for examination was made
Status updated on  23.10.2020
FormerThe international publication has been made
Status updated on  27.07.2019
Most recent event   Tooltip18.05.2024New entry: Despatch of examination report + time limit 
Applicant(s)For all designated states
Indiana University Research and Technology Corporation
518 Indiana Avenue
Indianapolis, IN 46202 / US
[2020/48]
Inventor(s)01 / PILI, Roberto
c/o Indiana University and Research Technology
Corporation 518 Indiana Ave.
Indianapolis, IN 46202 / US
 [2020/48]
Representative(s)Müller-Boré & Partner Patentanwälte PartG mbB
Friedenheimer Brücke 21
80639 München / DE
[2020/48]
Application number, filing date19740741.418.01.2019
[2020/48]
WO2019US14153
Priority number, dateUS201862619210P19.01.2018         Original published format: US 201862619210 P
US201862647282P23.03.2018         Original published format: US 201862647282 P
US201862679477P01.06.2018         Original published format: US 201862679477 P
[2020/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019143908
Date:25.07.2019
Language:EN
[2019/30]
Type: A1 Application with search report 
No.:EP3740210
Date:25.11.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 25.07.2019 takes the place of the publication of the European patent application.
[2020/48]
Search report(s)International search report - published on:US25.07.2019
(Supplementary) European search report - dispatched on:EP14.01.2022
ClassificationIPC:A61K31/404, A61K31/4166, A61K45/06, A61P35/00
[2021/45]
CPC:
A61P35/00 (EP,US); A61K31/404 (EP,US); A61K31/4166 (EP,US);
A61K45/06 (EP,US); G01N33/57419 (US)
C-Set:
A61K31/404, A61K2300/00 (EP);
A61K31/4166, A61K2300/00 (EP)
Former IPC [2020/48]A61K31/567, A61K31/4166, A61K45/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/48]
TitleGerman:THERAPEUTISCHES TARGETING VON DURCH REZEPTOR-TYROSINKINASE-INHIBITOR INDUZIERTER ANDROGENREZEPTORPHOSPHORYLIERUNG BEI KREBS[2020/48]
English:THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYLATION IN CANCER[2020/48]
French:CIBLAGE THÉRAPEUTIQUE D'UNE PHOSPHORYLATION DES RÉCEPTEURS AUX ANDROGÈNES INDUITE PAR UN INHIBITEUR DES RÉCEPTEURS À ACTIVITÉ TYROSINE KINASE DANS LE CANCER[2020/48]
Entry into regional phase13.08.2020National basic fee paid 
13.08.2020Search fee paid 
13.08.2020Designation fee(s) paid 
13.08.2020Examination fee paid 
Examination procedure13.08.2020Examination requested  [2020/48]
04.08.2022Amendment by applicant (claims and/or description)
17.05.2024Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
27.01.2021Renewal fee patent year 03
27.01.2022Renewal fee patent year 04
27.01.2023Renewal fee patent year 05
29.01.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2007004753  (SAWYERS CHARLES L [US], et al) [A] 1-6,9,10,14,15 * claim - *;
 [X]WO2010044893  (MERCK & CO INC [US], et al) [X] 1-3,5,14,15 * claims 1-4,9 *;
 [X]WO2014165779  (EXELIXIS INC [US]) [X] 1-4,9,10,14,15 * paragraph [0002] *;
 [X]  - ADELAIYE-OGALA REMI M. ET AL, "Abstract 4170: Targeting androgen receptor overcomes resistance to tyrosine kinase inhibitors in advanced clear cell renal cell carcinoma", CANCER RESEARCH, vol. 77, no. 13 Supplement, doi:10.1158/1538-7445.AM2017-4170, (20170701), URL: https://cancerres.aacrjournals.org/content/77/13_Supplement/4170, XP055842527 [X] 1-4,9,10,14,15 * abstract *

DOI:   http://dx.doi.org/10.1158/1538-7445.AM2017-4170
 [X]  - ARMSTRONG ANDREW J ET AL, "Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL, (20170511), vol. 81, doi:10.1016/J.EJCA.2017.02.030, ISSN 0959-8049, pages 228 - 236, XP085115689 [X] 1-3,6,14,15 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ejca.2017.02.030
 [X]  - MICHAEL A. GORDON ET AL, "Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer", MOLECULAR CANCER THERAPEUTICS, US, (20170503), vol. 16, no. 7, doi:10.1158/1535-7163.MCT-17-0111, ISSN 1535-7163, pages 1389 - 1400, XP055558198 [X] 1-3,5,14,15 * abstract *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-17-0111
 [X]  - EMMA K BEARDSLEY ET AL, "A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer", INVESTIGATIONAL NEW DRUGS, KLUWER ACADEMIC PUBLISHERS, BO, (20110723), vol. 30, no. 4, doi:10.1007/S10637-011-9722-5, ISSN 1573-0646, pages 1652 - 1659, XP035079550 [X] 1-4,9,10,14,15 * abstract *

DOI:   http://dx.doi.org/10.1007/s10637-011-9722-5
 [A]  - SÁNCHEZ-GASTALDO AMPARO ET AL, "Systemic treatment of renal cell cancer: A comprehensive review", CANCER TREATMENT REVIEWS, AMSTERDAM, NL, (20171101), vol. 60, doi:10.1016/j.ctrv.2017.08.010, ISSN 0305-7372, pages 77 - 89, XP055843836 [A] 1-6,9,10,14,15 * page 79 - page 83 *

DOI:   http://dx.doi.org/10.1016/j.ctrv.2017.08.010
 [A]  - QUINTELA MARTÍN LÁZARO ET AL, "Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor", CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL, (20150108), vol. 41, no. 3, doi:10.1016/J.CTRV.2014.12.006, ISSN 0305-7372, pages 247 - 253, XP029199333 [A] 1-6,9,10,14,15 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ctrv.2014.12.006
 [XP]  - ADELAIYE-OGALA REMI ET AL, "Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma", CANCER RESEARCH, (20180323), vol. 78, no. 11, doi:10.1158/0008-5472.CAN-17-3386, ISSN 0008-5472, pages 2886 - 2896, XP055841465 [XP] 1-6,9,10,14 * the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-17-3386
International search[A]WO2015049650  (GLAXOSMITHKLINE IP NO 2 LTD [GB]) [A] 1-4* Abstract *;
 [X]WO2017117182  (UNIV TEXAS [US]) [X] 1-4 * para [0003], [0012], [0039], [0044-0045] *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.